Goat anti-CYP7B1 Antibody | MyBioSource MBS420441 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

Goat anti-CYP7B1 Antibody

catalog :

MBS420441

quantity :

0.1 mg

price :

300 USD

clonality :

polyclonal

host :

goat

conjugate :

nonconjugated

reactivity :

human, cow

application :

immunohistochemistry, enzyme immunoassay

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS420441

products type :

Antibody

products full name :

Goat anti-CYP7B1 Antibody

products short name :

CYP7B1

products name syn :

CYP7B1; CP7B; cytochrome P450, family 7, subfamily B, polypeptide 1; oxysterol 7alpha-hydroxylase; cytochrome P450, subfamily VIIB (oxysterol 7 alpha-hydroxylase), polypeptide 1; CBAS3; SPG5A; CYP7B1 antibody; CP7B antibody; cytochrome P450; family 7; subfamily B; polypeptide 1 antibody; oxysterol 7alpha-hydroxylase antibody; cytochrome P450; subfamily VIIB (oxysterol 7 alpha-hydroxylase); polypeptide 1 antibody; CBAS3 antibody; SPG5A antibody

other names :

25-hydroxycholesterol 7-alpha-hydroxylase; 25-hydroxycholesterol 7-alpha-hydroxylase; 25-hydroxycholesterol 7-alpha-hydroxylase; cytochrome P450 family 7 subfamily B member 1; Cytochrome P450 7B1; Oxysterol 7-alpha-hydroxylase

products gene name :

CYP7B1

other gene names :

CYP7B1; CYP7B1; CP7B; CBAS3; SPG5A

uniprot entry name :

CP7B1_HUMAN

clonality :

Polyclonal

host :

Goat

reactivity :

Expected from sequence similarity: Human, Cow

sequence length :

506

sequence :

YPDSDVLFRYKVKS

purity :

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

form :

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

concentration :

100ug specific antibody in 200ul

storage stability :

Aliquot and store at -20 degree C. Minimize freezing and thawing.

tested application :

Peptide ELISA (EIA), Immunohistochemistry (IHC)

app notes :

Peptide ELISA: Antibody detection limit dilution 1: 128000. Immunohistochemistry: In paraffin embedded Human Breast shows textured cytoplasm staining in ductal epithelial cells. Recommended concentration, 3-6ug/ml. Western Blot: Preliminary experiments in Human Liver, Kidney and Prostate lysates gave no specific signal but low background (at antibody concentration up to 1ug/ml).

other info1 :

Immunogen: Peptide with sequence C-YPDSDVLFRYKVKS, from the C Terminus of the protein sequence according to NP_004811.1. Epitope: C Terminus

ncbi gi num :

4758104

ncbi acc num :

NP_004811.1

ncbi gb acc num :

NM_004820.3

ncbi mol weight :

58,256 Da

ncbi pathways :

Bile Acid And Bile Salt Metabolism Pathway (1270040); Biological Oxidations Pathway (1270189); Cytochrome P450 - Arranged By Substrate Type Pathway (1270191); Endogenous Sterols Pathway (1270192); Metabolism Pathway (1269956); Metabolism Of Lipids And Lipoproteins Pathway (1270001); Phase 1 - Functionalization Of Compounds Pathway (1270190); Primary Bile Acid Biosynthesis Pathway (82938); Primary Bile Acid Biosynthesis Pathway (299); Steroid Hormone Biosynthesis Pathway (82940)

ncbi summary :

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum membrane protein catalyzes the first reaction in the cholesterol catabolic pathway of extrahepatic tissues, which converts cholesterol to bile acids. This enzyme likely plays a minor role in total bile acid synthesis, but may also be involved in the development of atherosclerosis, neurosteroid metabolism and sex hormone synthesis. Mutations in this gene have been associated with hereditary spastic paraplegia (SPG5 or HSP), an autosomal recessive disorder. [provided by RefSeq, Apr 2016]

uniprot summary :

CYP7B1: Defects in CYP7B1 are the cause of spastic paraplegia autosomal recessive type 5A (SPG5A). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Defects in CYP7B1 are the cause of congenital bile acid synthesis defect type 3 (CBAS3). Clinical features include severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable. Belongs to the cytochrome P450 family. Protein type: Endoplasmic reticulum; Lipid Metabolism - primary bile acid biosynthesis; EC 1.14.13.100; Oxidoreductase. Chromosomal Location of Human Ortholog: 8q21.3. Cellular Component: endoplasmic reticulum membrane. Molecular Function: 25-hydroxycholesterol 7alpha-hydroxylase activity; heme binding; iron ion binding; oxysterol 7-alpha-hydroxylase activity. Biological Process: bile acid biosynthetic process; cholesterol metabolic process; negative regulation of estrogen receptor signaling pathway; positive regulation of epithelial cell proliferation; sterol metabolic process. Disease: Bile Acid Synthesis Defect, Congenital, 3; Spastic Paraplegia 5a, Autosomal Recessive

size1 :

0.1 mg

price1 :

300 USD

more info or order :

MyBioSource product webpage